[A22-122] Tezepelumab (severe asthma) – Benefit assessment according to § 35a SGB V
Last updated 15.02.2023
Project no.:
A22-122
Commission:
Commission awarded on 15.11.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Airways and respiratory system
Patients with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment
- Adolescents aged 12 to 17 years: added benefit not proven
- Adults: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-02-15.